After stroke, chondroitin sulfate proteoglycans (CSPGs) inhibit neuroblast migration and axon sprouting, but these effects can be blunted by modulating receptor-type tyrosine-protein phosphatase S (PTPsigma).
Alpha-therapy, in which alpha-particle-emitting radionuclides such as 227Th are delivered specifically to tumor tissues, is emerging as a novel strategy for targeted cancer therapy.
A new system for restoring cell function and tissues in mammals after death could expand the availability of organs for transplantation. The research also opens up a previously unexplored field of research in the molecular and cellular mechanisms triggered after death, an area of potential significance, since it covers different biological processes with multiple applications.
Lynk Pharmaceuticals' LNK-01004 has been cleared by China's National Medical Products Administration (NMPA) for clinical trials in the treatment of atopic dermatitis.
The FDA has cleared Jubilant Therapeutics' IND application for JBI-778, an oral, brain-penetrant and selective protein arginine methyl transferase 5 (PRMT5) inhibitor, for the treatment of solid tumors with brain metastases and primary brain tumors, including high-grade glioma.
Data from preclinical studies conducted to examine the activities of the novel estrogen receptor beta (ERbeta) agonist EGX-358, previously under study for the treatment of hot flushes at Estrigenix Therapeutics, for the potential treatment of Alzheimer's disease (AD) were presented at the recent Alzheimer's Association International Conference.
It has been previously demonstrated that MYCN amplification frequently occurs in high-risk neuroblastoma (NB), and it is correlated with an undifferentiated phenotype and poor prognosis.
RSS